Tags

Type your tag names separated by a space and hit enter

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
Am J Clin Nutr 2009; 89(2):641-51AJ

Abstract

BACKGROUND

Psychological distress (PD) and depressive symptoms are commonly observed during menopausal transition. Studies suggest that omega-3 (n-3) fatty acids may help alleviate depression.

OBJECTIVE

The objective was to compare enriched ethyl-eicosapentaenoic acid (E-EPA) supplementation with placebo for the treatment of PD and depressive symptoms in middle-aged women.

DESIGN

Women with moderate-to-severe PD (n = 120) were randomly assigned to receive 1.05 g E-EPA/d plus 0.15 g ethyl-docosahexaenoic acid/d (n = 59) or placebo (n = 61) for 8 wk. The main outcomes were 8-wk changes in PD scores [Psychological General Well-Being Schedule (PGWB)] and depressive scales [20-item Hopkins Symptom Checklist Depression Scale (HSCL-D-20) and the 21-item Hamilton Depression Rating Scale (HAM-D-21)].

RESULTS

At baseline, women with PD were mildly to moderately depressed, and 24% met the major depressive episode (MDE) criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. After 8 wk, outcomes improved in both groups, but no significant differences were noted between them. Stratification analyses for MDE diagnosis at baseline indicated that differences in adjusted 8-wk changes between the E-EPA group without MDE (n = 46) and the placebo group (n = 45) were 8.0 (95% CI: 0.6, 15.3; P = 0.034) for the PGWB, -0.2 (95% CI: -0.01, -0.4; P = 0.040) for the HSCL-D-20, and -2.7 (95% CI: -0.3, -5.1; P = 0.030) for the HAM-D-21. Differences in adjusted 8-wk changes between the E-EPA group with MDE (n = 13) and the placebo group (n = 16) were not significant.

CONCLUSIONS

To our knowledge, this is the first trial of n-3 supplementation in the treatment of PD and depressive symptoms in middle-aged women. In women with PD without MDE at baseline, the 8-wk changes in PD and depressive scales improved significantly more with E-EPA than with placebo. This trial was registered at http://www.controlled-trials.com as ISRCTN69617477.

Authors+Show Affiliations

Lucie and André Chagnon Chair for the Teaching of an Integrated Approach in Prevention, Laval University, Saint-François d'Assise Hospital (CHUQ), Quebec, Canada. michel.lucas@crchul.ulaval.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19116322

Citation

Lucas, Michel, et al. "Ethyl-eicosapentaenoic Acid for the Treatment of Psychological Distress and Depressive Symptoms in Middle-aged Women: a Double-blind, Placebo-controlled, Randomized Clinical Trial." The American Journal of Clinical Nutrition, vol. 89, no. 2, 2009, pp. 641-51.
Lucas M, Asselin G, Mérette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr. 2009;89(2):641-51.
Lucas, M., Asselin, G., Mérette, C., Poulin, M. J., & Dodin, S. (2009). Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. The American Journal of Clinical Nutrition, 89(2), pp. 641-51. doi:10.3945/ajcn.2008.26749.
Lucas M, et al. Ethyl-eicosapentaenoic Acid for the Treatment of Psychological Distress and Depressive Symptoms in Middle-aged Women: a Double-blind, Placebo-controlled, Randomized Clinical Trial. Am J Clin Nutr. 2009;89(2):641-51. PubMed PMID: 19116322.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. AU - Lucas,Michel, AU - Asselin,Geneviève, AU - Mérette,Chantal, AU - Poulin,Marie-Josée, AU - Dodin,Sylvie, Y1 - 2008/12/30/ PY - 2009/1/1/entrez PY - 2009/1/1/pubmed PY - 2009/2/12/medline SP - 641 EP - 51 JF - The American journal of clinical nutrition JO - Am. J. Clin. Nutr. VL - 89 IS - 2 N2 - BACKGROUND: Psychological distress (PD) and depressive symptoms are commonly observed during menopausal transition. Studies suggest that omega-3 (n-3) fatty acids may help alleviate depression. OBJECTIVE: The objective was to compare enriched ethyl-eicosapentaenoic acid (E-EPA) supplementation with placebo for the treatment of PD and depressive symptoms in middle-aged women. DESIGN: Women with moderate-to-severe PD (n = 120) were randomly assigned to receive 1.05 g E-EPA/d plus 0.15 g ethyl-docosahexaenoic acid/d (n = 59) or placebo (n = 61) for 8 wk. The main outcomes were 8-wk changes in PD scores [Psychological General Well-Being Schedule (PGWB)] and depressive scales [20-item Hopkins Symptom Checklist Depression Scale (HSCL-D-20) and the 21-item Hamilton Depression Rating Scale (HAM-D-21)]. RESULTS: At baseline, women with PD were mildly to moderately depressed, and 24% met the major depressive episode (MDE) criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. After 8 wk, outcomes improved in both groups, but no significant differences were noted between them. Stratification analyses for MDE diagnosis at baseline indicated that differences in adjusted 8-wk changes between the E-EPA group without MDE (n = 46) and the placebo group (n = 45) were 8.0 (95% CI: 0.6, 15.3; P = 0.034) for the PGWB, -0.2 (95% CI: -0.01, -0.4; P = 0.040) for the HSCL-D-20, and -2.7 (95% CI: -0.3, -5.1; P = 0.030) for the HAM-D-21. Differences in adjusted 8-wk changes between the E-EPA group with MDE (n = 13) and the placebo group (n = 16) were not significant. CONCLUSIONS: To our knowledge, this is the first trial of n-3 supplementation in the treatment of PD and depressive symptoms in middle-aged women. In women with PD without MDE at baseline, the 8-wk changes in PD and depressive scales improved significantly more with E-EPA than with placebo. This trial was registered at http://www.controlled-trials.com as ISRCTN69617477. SN - 1938-3207 UR - https://www.unboundmedicine.com/medline/citation/19116322/Ethyl_eicosapentaenoic_acid_for_the_treatment_of_psychological_distress_and_depressive_symptoms_in_middle_aged_women:_a_double_blind_placebo_controlled_randomized_clinical_trial_ L2 - https://academic.oup.com/ajcn/article-lookup/doi/10.3945/ajcn.2008.26749 DB - PRIME DP - Unbound Medicine ER -